All News

covid coronavirus virus

More severe COVID-19 outcomes in African American, Hispanic individuals with SLE

d Bella Mehta, MBBS, MS

A study from ACR21 convergence discussing data from the Global Rheumatology Alliance (GRA) describes the association between race/ethnicity on COVID-19 outcomes specifically in lupus patients.

Read Article
RheumNow Podcast square

RheumNow Podcast - ACR 2021 Rehash (the good stuff..)

d Jack Cush, MD

The ACR 2021 meeting has concluded. Dr. Jack Cush recounts a few more great abstracts from this past week’s virtual meeting.

Read Article
DPGN, lupus, nephritis, GN, glomerulonephritis, biopsy, kidney

Racial/ethnic disparity in U.S. lupus nephritis mortality

d Janet Pope, MD, MPH, FRCPC

At #ACR21, the plenary session included an analysis of deaths from SLE throughout the US comparing 1999 to 2019 (Abstract #0454).

Read Article
Sign

Emapalumab for the treatment of macrophage activation syndrome

d Md Yuzaiful Md Yusof, MRCP(UK), PhD

Macrophage activation syndrome (MAS) is a term commonly used by rheumatologists to describe a potentially life-threatening complication of systemic inflammatory disorders, most commonly occurring in people with systemic juvenile idiopathic arthritis (sJIA) and systemic lupus erythematosus (SLE).

Read Article
heel enthesitis spur calcaneal

Predicting RA, and Treatment of Subclinical Arthritis

d Meral K. El Ramahi, MD, FACP, FACR

Identifying patients that will develop RA in situations of seropositivity without overt clinical arthritis or identifying patients with undifferentiated oligo/polyarthritis that will develop RA remains a challenge in the field of rheumatology. 

Read Article
ICYMI: Dr. Aurelie Nahm ( @AurelieRheumo) shares #ACR21 presentation findings on TNF inhibitors and radiographic progression in axSpA https://t.co/nDh6sT1MzX https://t.co/5Ri13bfYOV

Links:

Dr. John Cush RheumNow ( View Tweet)
ICYMI: New Insights into Uveitis in Spondyloarthritis There have been some updates on uveitis in SpA at #ACR21 shared by Dr. Antoni Chan ( @synovialjoints). https://t.co/lyKt8p5s4o https://t.co/A9tRmD4mBJ https://t.co/TZPThjrazR

Links:

Dr. John Cush RheumNow ( View Tweet)
ICYMI: To Clot or Not to Clot with Drs. Janet Pope ( @Janetbirdope) and Jeffrey Sparks ( @jeffsparks ) #ACR21 https://t.co/HL6rGMqFRN https://t.co/YeWP4kKJhD https://t.co/7DyIXPPOLL

Links:

Dr. John Cush RheumNow ( View Tweet)
ICYMI: Monitoring Infliximab Drug Levels Improves Efficacy Should we start considering therapeutic drug monitoring when prescribing TNFi for treatment of our rheumatologic conditions? Dr. Robert Chao ( @doctorRBC) shares data presented at #ACR21. https://t.co/zkxvUrsczd

Links:

Dr. John Cush RheumNow ( View Tweet)

ICYMI: Watch: Lupus Updates: Dr. Michelle Petri Dr. Michelle Petri offers perspective and insight into lupus related data presented Saturday at the #ACR21 annual meeting. https://t.co/nluRreQPT1 https://t.co/fzm1RW6Rpy

Links:

Dr. John Cush RheumNow ( View Tweet)
In case you missed it… Watch: What's Cool and Hot in Vasculitis with Dr. Janet Pope (@Janetbirdope ) #ACR21 https://t.co/JbhQWeejy7 https://t.co/qlCCk3MXKu

Links:

Dr. John Cush RheumNow ( View Tweet)
ICYMI:Identifying Gaps in axSpA: Lessons from European Map of Axial Spondyloarthritis (EMAS) Dr. Sheila Reyes(@RHEUMarampa) discusses the three interesting abstracts were presented by the group of Prof. Marco Garrido-Cumbrera on the EMAS at #ACR21. https://t.co/5kOv5BUU4P https://t.co/lKuXC0mLRt

Links:

Dr. John Cush RheumNow ( View Tweet)
ICYMI: Risankizumab for Active Psoriatic Arthritis with Dr. Robert Chao ( @doctorRBC ) #ACR21 https://t.co/jRLem8YWpv https://t.co/5EQB1Y38Xs

Links:

Dr. John Cush RheumNow ( View Tweet)
ICYMI: COVID in Rheumatologic Disease Patients: Drs. Sparks, Liew, Yazdany and Dao provide an update on data specific to COVID in rheumatologic disease patients. @jeffsparks @drdavidliew @KDAO2011 #ACR21 https://t.co/jDGCpyTaPa https://t.co/58aehXyNzY

Links:

Dr. John Cush RheumNow ( View Tweet)
ICYMI: Towards better assessment and management of multimorbidity by Dr. Mrinalini Dey ( @DrMiniDey ) #ACR21 https://t.co/5G7PkWYrOH https://t.co/olsfrCyJw5

Links:

Dr. John Cush RheumNow ( View Tweet)
RheumNow Podcast - #ACR21 Rehash (the good stuff…) The ACR 2021 meeting has concluded. Dr. Jack Cush recounts a few more great abstracts from this past week’s virtual meeting. https://t.co/6tuiajP4O7 https://t.co/cZeeVmrHqR

Links:

Dr. John Cush RheumNow ( View Tweet)
Infections in ORAL Surveillance: Drs. Kevin Winthrop and Jonathan Kay https://t.co/GtMtUh33QE https://t.co/yjJngF25Y4

Links:

Dr. John Cush RheumNow ( View Tweet)
Does Obesity Play a Role in Biologic Response? Dr. Eric Dein ( @ejdein1) discusses abstract #0588 presented at the #ACR21 annual meeting. https://t.co/yJNOFv3KOC https://t.co/KvBrFlXLfW

Links:

Dr. John Cush RheumNow ( View Tweet)
Radiographic Progression in SpA: Dr. Antoni Chan ( @synovialjoints ) discusses abstract #0907 and #0897 presented at the #ACR21 annual meeting. https://t.co/9hStWrfPOW https://t.co/XkgDjXE7Aq

Links:

Dr. John Cush RheumNow ( View Tweet)
Can "Ultra-low" dose Rituximab work for RA? At day 3 of #ACR21, the REDO trial presented data in abs1443 in an oral presentation challenging how low we can go with rituximab for rheumatoid arthritis. Dr. Eric Dein ( @ejdein1) shares highlights. https://t.co/jaTjBPRKVe https://t.co/7Q9nxlUt7R

Links:

Dr. John Cush RheumNow ( View Tweet)
×